MAP2K7 and melanoma: Suppression of PHGDH can resensitize MEK inhibitor‐resistant NRASmut melanoma cells to trametinib treatment, increase the ability of cellular to combat oxidative stress, and decrease glutathione production and cell proliferation [393].